A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

Completed · Phase 1 · Has a placebo group

Conditions studied: Platelet Inhibition

In brief

The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane B2 inhibition.

Key facts

Study ID

NCT01094483

Run by

AstraZeneca

People needed

40

Starts

2010-03-01

Expected to finish

2010-05-01

Last updated by the study team

2010-12-07

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Stable without clinically significant disease

You may not qualify if…

• Use of NSAID within 2 weeks
• Type 1 or 2 DM
• GI disorder

Where it is running

• Research Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.